Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2005-10-26
pubmed:abstractText
The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status </=2 entered the study. Docetaxel 70 mg m(-2) was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-10655437, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-10758303, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-10873410, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-11600606, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-11981008, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-12504662, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-12648575, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-14758127, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-15169803, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-15459211, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-15721401, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-1987736, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-2033421, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-2407103, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-2703169, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-3055931, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-3754086, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-3953488, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-6539565, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-6871892, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-7105059, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-7190531, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-7670132, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-8111713, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-8256763, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-8751561, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-8898177, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-8922203, http://linkedlifedata.com/resource/pubmed/commentcorrection/16234823-9294478
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:day
31
pubmed:volume
93
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
999-1004
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
pubmed:affiliation
Department of Medical Oncology, National Cancer Center Hospital, 104-0045 Tokyo, Japan. nkatsuma@ncc.go.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II